Last May, the Food and Drug Administration (FDA) approved the company's second product, a vaccine for respiratory syncytial ...

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

Respiratory syncytial virus (RSV) is a cold-like illness ... working with payers “to carve immunization products out of bundled payments.” Below, we discuss the significant precedent for ...

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna.

CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ... authorization of our RSV vaccine is an important ...

CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products ... immunization for the prevention of lower respiratory ...